Login to Your Account

Astrazeneca’s pain is Relypsa’s gain as FDA stings HK drug ZS-9 with CRL

By Marie Powers
News Editor

Friday, May 27, 2016

Astrazeneca plc acknowledged receipt of a complete response letter (CRL) from the FDA on its new drug application (NDA) for sodium zirconium cyclosilicate, an oral suspension designed to treat hyperkalemia (HK). The candidate, better known as ZS-9, was the prize in Astrazeneca’s 2015 acquisition of ZS Pharma Inc. for $2.7 billion.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription